EUVIMEDEUVIMED entdecken
Crossref

Dual acting oxaliplatin (IV) prodrug loaded albumin nanoparticles for safer synergistic anticancer action against triple negative breast cancer

Kshitija Abhang, Sayali Dighe, Oly Katari, Vivek Yadav, Sanyog Jain iD

Drug Delivery and Translational Research · 2025-12 · 15 (12) · 4550-4570

DOI: 10.1007/s13346-025-01833-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Delivery and Translational Research, online erschienen am 11.03.2025. Verfasst von Kshitija Abhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Prodrugs, Nanoparticles, Oxaliplatin. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 75 Literaturangaben. Gefördert von: Science and Engineering Research Board (ASEAN-SERB).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Owing to faulty DNA damage repair system, triple negative breast cancer (TNBC) exhibits high susceptibility towards DNA damaging drugs such as platinum compounds e.g., oxaliplatin. Nevertheless, the clinical utility of oxaliplatin (OXA) has been constrained due to chemoresistance and chronic toxicities. Hence, to confer systemic inertness, tumor specific delivery, and multifaceted action, a octahedral OXA-CBL prodrug was synthesized using chlorambucil (CBL) as an axial ligand. The combination of OXA and CBL exhibited synergistic anti-cancer action in TNBC cell lines. Further, to potentiate the cellular internalization, targeting efficiency, and in-vivo performance, the synthesized prodrug was loaded into bovine serum albumin nanoparticles (OXA-CBL/BSA-NPs). The prepared nanoparticles had optimal particle size < 200 nm and high drug loading (∼ 5.863 ± 0.16%). As relative to free conjugate, the nanoparticles exhibited amplified cellular internalization and reduced the IC50 in 4T1 (∼ 1.38-fold) and MDA-MB-231 (∼ 1.43-fold) cell line. The anti-cancer study in 4T1-based TNBC model in BALB/c mice demonstrated significantly higher tumor inhibition rate, and reduced tumor burden in OXA-CBL/BSA-NPs treated group. Toxicity assessment revealed no signs of hepato- and/or renal toxicity. Also, nanoparticles exhibited sufficient compatibility with erythrocytes. Overall, delivery of OXA-CBL via virtue of albumin nanoparticles presents safer and efficacious approach to combat TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsProdrugsNanoparticlesOxaliplatinSerum Albumin, BovineAntineoplastic AgentsChlorambucilAnimalsFemaleHumansCell Line, TumorMice, Inbred BALB CMiceDrug Synergism

Stichwörter der Autor:innen

AlbuminChlorambucilOxaliplatinPlatinum prodrugsTriple negative breast cancer

Substanzen

ProdrugsOxaliplatinSerum Albumin, BovineAntineoplastic AgentsChlorambucil

Autor:innen und Institutionen

  • Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67 S.A.S. Nagar, Punjab, 160062, India.
  • Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67 S.A.S. Nagar, Punjab, 160062, India. sanyogjain@niper.ac.in.

ORCID-Profile: Sanyog Jain

Förderung

  • Science and Engineering Research Board (ASEAN-SERB)

Zitieren

APA

Abhang, K., Dighe, S., Katari, O., Yadav, V., & Jain, S. (2025). Dual acting oxaliplatin (IV) prodrug loaded albumin nanoparticles for safer synergistic anticancer action against triple negative breast cancer. Drug Delivery and Translational Research, 15(12), 4550-4570. https://doi.org/10.1007/s13346-025-01833-9

Vancouver

Abhang K, Dighe S, Katari O, Yadav V, Jain S. Dual acting oxaliplatin (IV) prodrug loaded albumin nanoparticles for safer synergistic anticancer action against triple negative breast cancer. Drug Delivery and Translational Research. 2025;15(12):4550-4570. doi:10.1007/s13346-025-01833-9

BibTeX
@article{Abhang2025,
  author = {Abhang, Kshitija and Dighe, Sayali and Katari, Oly and Yadav, Vivek and Jain, Sanyog},
  title = {Dual acting oxaliplatin (IV) prodrug loaded albumin nanoparticles for safer synergistic anticancer action against triple negative breast cancer},
  journal = {Drug Delivery and Translational Research},
  year = {2025},
  volume = {15},
  number = {12},
  pages = {4550--4570},
  doi = {10.1007/s13346-025-01833-9}
}
Kostenlos starten →